TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Body-weight Supported Therapy Using Gait Trainer Versus Traditional Gait-oriented Physiotherapy in Acute Phase of Stroke. The Effectiveness of Gait Training and Brain Networks Using NBS (Navigating Brain Stimulation)
Brief Summary: This is a trial aiming to evaluate the difference of effectiveness between two therapy methods in patients with acute stroke. The other aim is to use Navigated Brain Stimulation (NBS)to analyze changes in brain networks during the recovery and as the consequence of rehabilitation. The groups are:

* body-weight supported gate trainer rehabilitation
* gait-oriented traditional physiotherapy Patients in physiotherapy group will have 75 min physiotherapy daily every workday. This includes 20 minutes walking exercises in the traditional group while 20 minutes of gait trainer therapy in the gait trainer group. The evaluation of effectiveness of therapy in each group is made after three weeks' therapy and at six months. The goal is to have 40 patients until the end of June 2006.


Options:
A: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program
B: Arm Label: Motor Learning Walking Program; Type: EXPERIMENTAL; Interventions: Behavioral: Motor Learning Walking Program | Arm Label: Body weight supported treadmill training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Body Weight Supported Treadmill Training | Intervention Type: BEHAVIORAL; Name: Motor Learning Walking Program; Assigned to Arm(s): Motor Learning Walking Program | Intervention Type: BEHAVIORAL; Name: Body Weight Supported Treadmill Training; Assigned to Arm(s): Body weight supported treadmill training
C: Intervention Type: PROCEDURE; Name: exercise therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: walking rehabilitation; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: intensified gait trainer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: intensified gait trainer | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intensified gait trainer; Assigned to Arm(s): 1, 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Association Amongst Acupuncture Analgesia, Expectancy, and Psychiatric Comorbidity in Patients With Low Back Pain
Brief Summary: It is our hypothesis that patient's expectations concerning treatment outcome will be influenced by their psychiatric symptoms, and that this expectancy will have a strong influence on the efficacy of acupuncture treatment to suppress experimentally induced pain. We will conduct a study, monitoring expectations but not manipulating them, in a cohort of patients with chronic low back pain.


Options:
A: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care
B: Arm Label: French ear acupuncture; Type: EXPERIMENTAL; Interventions: Device: French ear acupuncture | Arm Label: Sham Ultrasound; Type: PLACEBO_COMPARATOR; Interventions: Other: Sham Ultrasound | Intervention Type: DEVICE; Name: French ear acupuncture; Assigned to Arm(s): French ear acupuncture | Intervention Type: OTHER; Name: Sham Ultrasound; Assigned to Arm(s): Sham Ultrasound
C: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non needle control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Acupuncture - Standardized Points; Type: SHAM_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Accupunture - Experimental Points; Type: EXPERIMENTAL; Interventions: Procedure: Accupuncture | Intervention Type: PROCEDURE; Name: Accupuncture; Assigned to Arm(s): Accupunture - Experimental Points, Acupuncture - Standardized Points, non needle control
D: Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.


Options:
A: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: novasure; Type: ACTIVE_COMPARATOR; Interventions: Device: NovaSure | Arm Label: thermachoice; Type: OTHER; Interventions: Device: thermachoice | Intervention Type: DEVICE; Name: NovaSure; Assigned to Arm(s): novasure | Intervention Type: DEVICE; Name: thermachoice; Assigned to Arm(s): thermachoice
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid tablets | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablets | Intervention Type: DRUG; Name: Tranexamic acid tablets; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo tablets; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, 7 Cycle Duration (196 Days), Phase 3 Study of Oral Estradiol Valerate/Dienogest Tablets for the Treatment of Dysfunctional Uterine Bleeding.
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.


Options:
A: Intervention Type: DRUG; Name: Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol; Assigned to Arm(s): N/A
B: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: Provera; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Combination Birth Control pills; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release on Glucose Control (HbA1c) and Safety in Subjects With Type 2 Diabetes Mellitus Managed With Diet Modification and Exercise and/or Oral Antidiabetic Medications
Brief Summary: A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet Modification and Exercise and/or Oral Antidiabetic Medications.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Taspoglutide 20mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg | Arm Label: Taspoglutide 20mg-30mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg-30mg | Arm Label: Taspoglutide 20mg-40mg; Type: EXPERIMENTAL; Interventions: Drug: Taspoglutide 20mg-40mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Taspoglutide 20mg; Assigned to Arm(s): Taspoglutide 20mg | Intervention Type: DRUG; Name: Taspoglutide 20mg-30mg; Assigned to Arm(s): Taspoglutide 20mg-30mg | Intervention Type: DRUG; Name: Taspoglutide 20mg-40mg; Assigned to Arm(s): Taspoglutide 20mg-40mg
B: Arm Label: Exenatide Once Weekly; Type: EXPERIMENTAL; Interventions: Drug: exenatide, long acting release | Arm Label: Exenatide Twice Daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: exenatide, long acting release; Assigned to Arm(s): Exenatide Once Weekly | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide Twice Daily
C: Arm Label: Lira placebo/Lira 2.4 mg/Lira 3.0 mg; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Lira 1.2 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 1.8 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Lira 2.4 mg/Lira 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: liraglutide, Drug: placebo | Arm Label: Orlistat; Type: ACTIVE_COMPARATOR; Interventions: Drug: orlistat | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Lira 1.2 mg/Lira 3.0 mg, Lira 1.8 mg/Lira 3.0 mg, Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg | Intervention Type: DRUG; Name: orlistat; Assigned to Arm(s): Orlistat | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Lira placebo/Lira 2.4 mg/Lira 3.0 mg, Liraglutide 3.0 mg
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Exenatide Once Weekly | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine | Intervention Type: DRUG; Name: Exenatide Once Weekly; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Tapering or Standard Steroids for Nephrotic Syndrome
Brief Summary: Parallel group double blind randomised in patients with first episode corticosteroid sensitive nephrotic syndrome comparing time to relapse and adverse effects associated with a longer tapering steroid regimen with standard regime


Options:
A: Arm Label: Intervention: Prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Intervention: Prednisolone
B: Intervention Type: DRUG; Name: long term tapering of prednisolone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: standard prednisolone treatment; Assigned to Arm(s): N/A
C: Arm Label: High dose prednisolone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Arm Label: Alfacalcidol and low dose prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Drug: Alfacalcidol | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Alfacalcidol and low dose prednisolone, High dose prednisolone | Intervention Type: DRUG; Name: Alfacalcidol; Assigned to Arm(s): Alfacalcidol and low dose prednisolone
D: Arm Label: B-Experimental; Type: EXPERIMENTAL; Interventions: Drug: acid mycophenolic (Myfortic) | Arm Label: A-Active Comparator; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisone | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): A-Active Comparator | Intervention Type: DRUG; Name: acid mycophenolic (Myfortic); Assigned to Arm(s): B-Experimental

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Risperidone Alone Vs. Risperidone Plus Valproate in the Treatment of Patients With Schizophrenia and Hostility
Brief Summary: This is an eight-week open-label randomized parallel group clinical trial focusing on the comparison of risperidone alone with risperidone plus valproate among hospitalized adult patients diagnosed with schizophrenia who also exhibit problems with hostility. Patients may have already been receiving risperidone or valproate (but not both) at study entry. Patients not receiving valproate at study entry were randomized to receive either risperidone alone or risperidone with valproate. For patients already receiving valproate at study entry, their antipsychotic medication(s) was switched to risperidone, and they were followed for a four-week lead-in period prior to baseline assessment and randomization to receive risperidone alone or continue with risperidone and valproate. We hypothesized that risperidone alone has an antiaggressive/antihostility effect, and that this effect is augmented by the co-administration of valproate.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Risperidone low dose | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Risperidone high dose | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Risperidone high dose; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Risperidone low dose; Assigned to Arm(s): 001
B: Arm Label: Asenapine; Type: EXPERIMENTAL; Interventions: Drug: Asenapine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asenapine; Assigned to Arm(s): Asenapine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Risperidone, divalproex; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase IIIb Open-label Induction and Double-blind Comparison of 2 Maintenance Schedules Evaluating Clinical Benefit and Tolerability of Certolizumab Pegol in Crohn's Disease Patients With Prior Loss of Response or Intolerance to Infliximab
Brief Summary: To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab


Options:
A: Arm Label: Certolizumab Pegol; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CDP870) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): Certolizumab Pegol
B: Arm Label: Certolizumab pegol; Type: EXPERIMENTAL; Interventions: Biological: certolizumab pegol (CDP870, CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: certolizumab pegol (CDP870, CZP); Assigned to Arm(s): Certolizumab pegol | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Active 1; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol, Other: Placebo | Arm Label: Active 2; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 1 | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): Active 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Active 1
D: Arm Label: CDP870 400 mg; Type: EXPERIMENTAL; Interventions: Biological: Certolizumab pegol | Intervention Type: BIOLOGICAL; Name: Certolizumab pegol; Assigned to Arm(s): CDP870 400 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare two methods of delivering Nasal Continuous Airway Pressure (NCPAP): Biphasic Mode and a continuous mode, to see which is better in getting babies off the ventilator and decreasing lung damage.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Biphasic Infant flow NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP | Intervention Type: PROCEDURE; Name: Biphasic Infant flow NCPAP; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): 2
B: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
D: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare two methods of delivering Nasal Continuous Airway Pressure (NCPAP): Biphasic Mode and a continuous mode, to see which is better in getting babies off the ventilator and decreasing lung damage.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Biphasic Infant flow NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP | Intervention Type: PROCEDURE; Name: Biphasic Infant flow NCPAP; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): 2
B: Arm Label: NHFOV; Type: EXPERIMENTAL; Interventions: Device: NHFOV | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NHFOV; Assigned to Arm(s): NHFOV | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): NIPPV
C: Arm Label: Nasal Continuous Positive Airway Pressure (CPAP); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal CPAP (SLE) | Arm Label: Nasal Intermittent Mandatory Ventilation (IMV); Type: ACTIVE_COMPARATOR; Interventions: Device: Nasal IMV (SLE) | Intervention Type: DEVICE; Name: Nasal CPAP (SLE); Assigned to Arm(s): Nasal Continuous Positive Airway Pressure (CPAP) | Intervention Type: DEVICE; Name: Nasal IMV (SLE); Assigned to Arm(s): Nasal Intermittent Mandatory Ventilation (IMV)
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Flow Biphasic NCPAP Versus Infant Flow NCPAP for the Facilitation of Successful Extubation in Infants </= 1250 Grams: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to compare two methods of delivering Nasal Continuous Airway Pressure (NCPAP): Biphasic Mode and a continuous mode, to see which is better in getting babies off the ventilator and decreasing lung damage.


Options:
A: Arm Label: NIPPV; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): Control, NIPPV
B: Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: nasal intermittent positive pressure ventilation | Arm Label: NIPPV; Type: EXPERIMENTAL; Interventions: Device: nasal intermittent positive pressure ventilation | Intervention Type: DEVICE; Name: nasal intermittent positive pressure ventilation; Assigned to Arm(s): NCPAP, NIPPV
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Device: NIPPV | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Device: nCPAP | Intervention Type: DEVICE; Name: nCPAP; Assigned to Arm(s): B | Intervention Type: DEVICE; Name: NIPPV; Assigned to Arm(s): A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Biphasic Infant flow NCPAP | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CPAP | Intervention Type: PROCEDURE; Name: Biphasic Infant flow NCPAP; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: CPAP; Assigned to Arm(s): 2

Answer: D